Loading clinical trials...
Loading clinical trials...
A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
Conditions
Interventions
Tivozanib
Durvalumab
Locations
10
United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
City of Hope
Duarte, California, United States
University of California - Irvine
Orange, California, United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
September 30, 2019
Primary Completion Date
April 4, 2023
Completion Date
April 4, 2023
Last Updated
July 12, 2023
NCT07485114
NCT06811116
NCT06066138
NCT06345508
NCT04380545
NCT07291076
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions